Teva Pharmaceutical Industries announced the release of limited doses of the FDA-approved generic version of EpiPen1 (epinephrine injection, USP) Auto-Injector, 0.3 mg, in the U.S.
Teva’s generic version of the EpiPen Jr (epinephrine injection, USP) Auto-Injector, 0.15 mg, and an additional supply of Teva’s generic version of the EpiPen (epinephrine injection, USP) Auto-Injector, 0.3 mg is expected in 2019. The publically available Wholesale Acquisition Cost (WAC)2 for the product is $300.
Brendan O’Grady, EVP and head of North America Commercial at Teva said, “We’re pleased to provide access to Epinephrine Injection (Auto-Injector) for patients who may experience life-threatening allergic emergencies and we’re fully dedicated toward ensuring additional supply in 2019.”
With over 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market. Currently, one in seven generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
1 EpiPen and EpiPen Jr are registered trademarks of Mylan.
2 Teva does not set the price that a pharmacy charges for a particular drug and does not has visibility or control into the price of the drug in the marketplace.
(Source: Teva Pharmaceutical Industries)